Clinical Trial Update: Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of durvalumab and tremelimumab in participants with recurrent or treatment-refractory ovarian, fallopian tube, or pri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Status: COMPLETED